Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab

Claudia Fabiani, Antonio Vitale, Donato Rigante, Giacomo Emmi, Giuseppe Lopalco, Jurgen Sota, Lorenzo Vannozzi, Gerardo di Scala, Silvana Guerriero, Ida Orlando, Rossella Franceschini, Marco Capozzoli, Bruno Frediani, Mauro Galeazzi, Florenzo Iannone, Gian Marco Tosi, Luca Cantarini

Research output: Contribution to journalArticle

Abstract

To identify clinical variables capable of predicting long-term treatment duration of TNF-α inhibition in patients with Behçet’s disease (BD)-related uveitis. Demographic, clinical, and therapeutic data were retrospectively collected from BD patients treated with the tumor necrosis factor (TNF)-α blockers infliximab and adalimumab. Patients still continuing TNF-α inhibitors at 48-month follow-up visits were classified as long-term responders and were statistically compared to patients discontinuing treatment before the 48-month visit. Forty-five patients (75 eyes) were enrolled. Thirty-two patients continued anti-TNF-α treatment for more than 48 months; 13 patients discontinued the treatment after a mean time of 12.3 ± 10.44 months due to lack (61.5%) or loss (38.5%) of efficacy. Baseline value of BD current activity form was the only variable discriminating long- and short-term responsive patients (p = 0.048, OR = 0.656, C.I. 95% 0.433–0.996). Disease activity levels at the start of treatment predict duration of response to monoclonal TNF antagonists in ocular BD.

Original languageEnglish
Pages (from-to)1715-1720
Number of pages6
JournalClinical Rheumatology
Volume37
Issue number6
DOIs
Publication statusPublished - Jun 1 2018

Keywords

  • Behçet’s disease
  • Disease activity
  • Long-term efficacy
  • Treatment
  • Uveitis

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab'. Together they form a unique fingerprint.

  • Cite this

    Fabiani, C., Vitale, A., Rigante, D., Emmi, G., Lopalco, G., Sota, J., Vannozzi, L., di Scala, G., Guerriero, S., Orlando, I., Franceschini, R., Capozzoli, M., Frediani, B., Galeazzi, M., Iannone, F., Tosi, G. M., & Cantarini, L. (2018). Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab. Clinical Rheumatology, 37(6), 1715-1720. https://doi.org/10.1007/s10067-018-4092-4